Martine Rothblatt, who serves as Chairperson and Chief Executive Officer of United Therapeutics (NASDAQ: UTHR), completed a block of stock sales on April 10, 2026 that amounted to approximately $5.4 million. The sales consisted of 9,490 shares of common stock executed at prices between $567.2438 and $573.0088.
The share sales coincided with United Therapeutics trading near its 52-week peak of $607.89, following a 103% increase in the company’s share price over the preceding 12 months. An InvestingPro analysis included with the company data indicates the stock currently appears overvalued relative to its Fair Value.
In connection with the same set of transactions, Rothblatt also exercised stock options covering 9,500 shares of United Therapeutics common stock at an exercise price of $146.03, resulting in proceeds of $1387285 tied to that exercise.
All of these moves were executed under a pre-arranged 10b5-1 trading plan that Rothblatt adopted on November 7, 2025. The plan is structured to remain in force until one of two conditions is met - either until 1,734,410 stock options are exercised (all of which expire on March 17, 2027) or until December 31, 2026.
After the April 10 transactions, Rothblatt holds 40,513 shares of United Therapeutics directly. The public profile for the company shows a market capitalization of $25.35 billion and a reported gross profit margin of 87.92%. The company’s filings also indicate Rothblatt has indirect holdings through ownership by spouse, by Trust.
Separately, United Therapeutics has reported a number of material corporate and clinical developments in recent weeks. The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to miroliverELAP, an investigational liver assist device aimed at supporting patients with acute liver failure.
Analyst activity has been notable as well. Raymond James initiated coverage on United Therapeutics with an Outperform rating and a $700 price target, citing the potential for Tyvaso to achieve peak sales of over $5 billion in idiopathic pulmonary fibrosis (IPF). H.C. Wainwright lifted its price target to $660 and maintained a Buy rating, referencing encouraging TETON-1 trial data for Tyvaso in IPF. Bank of America Securities raised its target to $626 while keeping a Neutral rating, pointing to positive Phase 3 trial results. Jefferies moved its price objective to $733, held a Buy rating, and updated probability of success assumptions to 95% for Tyvaso’s IPF indication and 70% for progressive pulmonary fibrosis based on recent trial outcomes.
Collectively, the insider transactions and the recent regulatory and analyst actions form the latest set of disclosures that market participants can use to assess United Therapeutics’ position as the company advances its clinical programs and commercial expectations.